This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB05266/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB05266/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/mesh/concept/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05266/identifier/bindingdb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB05266/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/drugbank/drug/DB05266/identifier/pubchem-substance/
n18http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB05266/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB05266/identifier/chemspider/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05266
rdf:type
n4:Drug
n4:description
Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.
n4:group
investigational approved
n4:halfLife
19 hours
n4:indication
For the treatment of multiple sclerosis, asthma, and cerebrovascular disease.
owl:sameAs
n9:DB05266 n18:DB05266
dcterms:title
Ibudilast
adms:identifier
n11:50240404 n12:3543 n13:PA165958351 n14:Ibudilast n15:99443231 n16:DB05266 n17:3671
n4:mechanismOfAction
Ibudilast has mechanisms that include anti-inflammatory effects, such as phosphodiesterase inhibition, and neuroprotective effects, such as inhibition of [nitric oxide] synthesis and reduction in reactive oxygen species.
n4:synonym
Ke tas Ketas 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine Ibudilast AV-411 3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine Ibudilastum Pyrazolo(1,5-a)pyridine, 3-isobutyryl-2-isopropyl- Eyevinal Ketas (TN) 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine MN-166 Tocris-1694
n4:toxicity
Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia
n6:hasConcept
n7:M0115560
n4:IUPAC-Name
n5:271B3F90-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B3F96-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B3F95-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B3F92-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B3F93-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B3F94-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B3F8E-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B3F8C-363D-11E5-9242-09173F13E4C5 n5:271B3F8F-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B3F8D-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:R03DC04
n4:H-Bond-Acceptor-Count
n5:271B3F9C-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B3F9D-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B3F97-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B3F98-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B3F9A-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B3F99-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B3F9B-363D-11E5-9242-09173F13E4C5
n4:affectedOrganism
Humans and other mammals
n4:casRegistryNumber
50847-11-5
n4:category
n4:Bioavailability
n5:271B3FA2-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B3FA4-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B3FA5-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B3FA1-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B3FA0-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B3FA3-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B3F91-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-acidic-
n5:271B3F9E-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B3F9F-363D-11E5-9242-09173F13E4C5